French Agency for Food, Environmental and Occupational Health & Safety (Anses), Risk Assessment Department, France.
Regul Toxicol Pharmacol. 2013 Feb;65(1):7-11. doi: 10.1016/j.yrtph.2012.11.010. Epub 2012 Dec 2.
The French Agency for Food, Environmental and Occupational Health and Safety (Anses) hosted a two-day workshop on Endocrine Disruptors: Exposure and Potential Impact on Consumers Health, bringing together participants from international organizations, academia, research institutes and from German, Swedish, Danish and French governmental agencies. The main objective of the workshop was to share knowledge and experiences on endocrine disruptors (ED) exposure and potential impact on consumers' health, to identify current risk assessment practices and knowledge gaps and issue recommendations on research needs and future collaboration. The following topics were reviewed: (1) Definition of ED, (2) endpoints to be considered for Risk assessment (RA) of ED, (3) non-monotonic dose response curves, (4) studies to be considered for RA (regulatory versus academic studies), (5) point of departure and uncertainty factors, (6) exposure assessment, (7) regulatory issues related to ED. The opinions expressed during this workshop reflect day-to-day experiences from scientists, regulators, researchers, and others from many different countries in the fields of risk assessment, and were regarded by the attendees as an important basis for further discussions. Accordingly, the participants underlined the need for more exchange in the future to share experiences and improve the methodology related to risk assessment for endocrine disrupters.
法国食品、环境和职业健康安全局(Anses)举办了为期两天的关于内分泌干扰物:暴露和对消费者健康的潜在影响的研讨会,来自国际组织、学术界、研究机构以及德国、瑞典、丹麦和法国政府机构的代表参加了会议。研讨会的主要目的是分享关于内分泌干扰物(ED)暴露和对消费者健康的潜在影响的知识和经验,确定当前的风险评估实践和知识差距,并就研究需求和未来合作提出建议。会议审查了以下主题:(1)ED 的定义,(2)ED 风险评估(RA)要考虑的终点,(3)非线性剂量反应曲线,(4)RA 要考虑的研究(监管研究与学术研究),(5)起始点和不确定因素,(6)暴露评估,(7)与 ED 相关的监管问题。本次研讨会期间表达的意见反映了来自不同国家的风险评估领域的科学家、监管机构、研究人员和其他人员的日常经验,与会者认为这是进一步讨论的重要基础。因此,与会者强调需要在未来进行更多的交流,以分享经验并改进与内分泌干扰物风险评估相关的方法。